Back to CAI Overview
NMS · Valuation Lab
CAI
Caris Life Sciences, Inc.
Last$16.45
Market cap4.7B
EV/EBITDA33.0x
Intrinsic value
$166.62
MoS +90.1% · Undervalued
Assuming 11.2% FCF margin and 60.0% Y1–5 growth.
Upside to price
EV (DCF)46.7B
Terminal share80%
Expected IV$175.55
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 80% of EV
PV of stage FCFs9.5B
PV of terminal value37.2B
Enterprise value46.7B
Net cash / (debt)392.5M
Equity value47.1B
Intrinsic value / share$166.62
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 1.5B | 162.6M | 149.1M | 91.7% |
| Y2 | 2.3B | 260.1M | 218.9M | 84.1% |
| Y3 | 3.7B | 416.2M | 321.2M | 77.2% |
| Y4 | 5.9B | 666M | 471.4M | 70.8% |
| Y5 | 9.5B | 1.1B | 691.9M | 64.9% |
| Y6 | 13.3B | 1.5B | 884.7M | 59.6% |
| Y7 | 18.5B | 2.1B | 1.1B | 54.6% |
| Y8 | 25.8B | 2.9B | 1.4B | 50.1% |
| Y9 | 35.9B | 4B | 1.8B | 46.0% |
| Y10 | 50.1B | 5.6B | 2.4B | 42.2% |
| Terminal | — | — | 37.2B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.